Xilio Therapeutics Appoints Paul J. Clancy to its Board of Directors

Mr. Clancy brings significant strategic, financial and operational leadership experience in the biotechnology and pharmaceutical industry

WALTHAM, Mass.--(BUSINESS WIRE)--Xilio Therapeutics, a company developing potent, tumor-selective immunotherapies for patients with cancer, today announced the appointment of Paul J. Clancy to its Board of Directors. Mr. Clancy is an accomplished biopharmaceutical executive with a strong track record of building and leading successful global biotechnology companies.

“Paul is a highly respected leader in the biotechnology community and brings a wealth of strategic and operational experience that will support Xilio through this stage of rapid growth of the company,” said Rene Russo, Chief Executive Officer of Xilio. “Paul’s demonstrated commitment to bringing meaningful, life changing therapies to patients around the world resonates strongly with our mission, and we are excited to welcome him to the Xilio Board of Directors.”

Mr. Clancy has more than 30 years of experience in corporate and financial leadership and strategic business planning.  He currently serves on the boards of Agios Pharmaceuticals and Incyte Corporation. Mr. Clancy was Executive Vice President and Chief Financial Officer for Alexion Pharmaceuticals from July 2017 to October 2019.  Prior to that, Mr. Clancy was Executive Vice President and Chief Financial Officer of Biogen.  While at Biogen, he successfully led the financial strategy of the company over a ten-year period of growth.  Mr. Clancy joined Biogen in 2001, where he also served in several other senior executive positions, including Senior Vice President of Finance, Vice President of Business Planning, Vice President of Portfolio Management, and Vice President of Marketing.  Prior to Biogen, he spent thirteen years at PepsiCo in a range of finance, strategy, and general management positions.  Mr. Clancy received his B.S. in Finance from Babson College and M.B.A. from Columbia University.

“Xilio Therapeutics is at an exciting stage in its growth trajectory and has the potential to be a leader in developing highly potent immunotherapies that are selectively activated in tumors,” said Mr. Clancy. “I look forward to the opportunity to contribute to the company’s important mission to transform the lives of patients living with cancer.”

Xilio Therapeutics is developing its proprietary technology to create a new class of ultra-potent immunotherapies that are activated selectively within the tumor. These tumor-selective therapies are designed to overcome the significant toxicities associated with clinically validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment. XTX201 (IL-2) and XTX101 (aCTLA4 mAb) have demonstrated tumor-selective activity in preclinical models, significantly widening the potential therapeutic index for these therapies.

About Xilio Therapeutics

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines.

Xilio was founded in 2016 and is headquartered in Waltham, Mass. For more information, please visit www.xiliotx.com.